By Fineline Cube Sino Biopharmaceutical Limited (HKG: 1177) announced that benmelstobart in combination with chemotherapy, sequentially followed by anlotinib, has been granted marketing approval by China’s National Medical Products Administration (NMPA) for the first‑line treatment of locally advanced or metastatic squamous non‑small cell lung cancer (sq‑NSCLC). Both drugs are Category 1 innovative medicines developed by Sino Biopharma’s subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ). This marks the 12th approved indication for anlotinib and the 6th approved indication for benmelstobart.
Approval Snapshot
| Item | Detail |
|---|---|
| Company | Sino Biopharmaceutical Limited (HKG: 1177) |
| Subsidiary | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ) |
| Agency | NMPA (China) |
| Approval Type | Marketing approval (Category 1 innovative drug) |
| Regimen | Benmelstobart + chemotherapy → anlotinib + benmelstobart (sequential) |
| Indication | First‑line locally advanced or metastatic sq‑NSCLC |
| Approval Date | 07 Aug 2026 |
| Indication Tally | Anlotinib: 12th; Benmelstobart: 6th |
Drug Profile & Mechanism of Action
- Benmelstobart: Anti‑PD‑L1 monoclonal antibody (mAb); blocks the programmed death‑ligand 1 pathway to restore T‑cell‑mediated anti‑tumor immunity.
- Anlotinib: Oral multi‑target tyrosine kinase inhibitor; suppresses tumor angiogenesis and proliferation by inhibiting VEGFR, PDGFR, FGFR, and c‑Kit, among other targets.
- Combination Rationale: Sequential immunotherapy plus targeted anti‑angiogenesis aims to overcome primary resistance and extend durable disease control beyond what either monotherapy or chemo‑immunotherapy alone typically achieves.
- Prior Indications in China: Endometrial cancer, extensive‑stage small cell lung cancer (ES‑SCLC), and first‑line renal cell carcinoma, among others.
Clinical Evidence – ETER700 Phase 3 Trial
| Endpoint | Benmelstobart + Chemo → Anlotinib + Benmelstobart | Tislelizumab + Chemo (Control) | Benefit |
|---|---|---|---|
| mPFS | 11.20 months | 8.28 months | +2.92 months |
| mOS | Not reached | 26.45 months | Statistically significant |
| ORR | 76.33 % | 71.78 % | +4.55 ppt |
| mDoR | 13.14 months | 11.07 months | +2.07 months |
| Discontinuation Due to AEs | 8.8 % | 9.8 % | –1.0 ppt |
The head‑to‑head study demonstrated consistent benefits across subgroups, including patients with varying PD‑L1 expression levels. The safety profile was manageable, with a slightly lower rate of treatment discontinuation due to adverse events in the study arm versus the control arm.
Market Impact & Outlook
- China sq‑NSCLC Landscape: Squamous NSCLC accounts for roughly 25–30 % of all lung cancer cases in China and has historically been challenging to treat due to limited targeted therapy options outside of immunotherapy combinations. A domestically developed, sequential chemo‑immuno‑TKI regimen offers a new standard‑of‑care contender.
- Head‑to‑Head Differentiation: By beating tislelizumab (BeiGene’s blockbuster PD‑1 inhibitor) on both PFS and OS in a direct comparison, the benmelstobart‑anlotinib regimen gains a compelling commercial narrative for hospital formulary inclusion and physician adoption.
- Portfolio Synergy: With 12 indications for anlotinib and 6 for benmelstobart, CTTQ is building a broad‑based oncology franchise that leverages cross‑selling and combination‑therapy bundling across multiple tumor types.
- Revenue Forecast: Analysts estimate the China first‑line sq‑NSCLC market could exceed ¥8 billion (≈ US$1.1 billion) annually by 2028. Sino Biopharma’s sequential regimen, if priced competitively against imported PD‑1/PD‑L1 combinations, could capture a meaningful share of this volume.
- Pipeline Momentum: Additional combination trials in other solid tumors are expected to read out over the next 12–18 months, potentially expanding the label further.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the commercial potential of the benmelstobart‑anlotinib combination in China, revenue projections, and future pipeline developments. Actual results may differ materially due to risks including reimbursement negotiations, competitive dynamics, physician adoption rates, and regulatory requirements for new indications. Investors should consult official filings for updated risk factors.-Fineline Info & Tech